Avalo Therapeutics (AVTX) Net Margin (2016 - 2024)
Historic Net Margin for Avalo Therapeutics (AVTX) over the last 9 years, with Q4 2024 value amounting to 18405.73%.
- Avalo Therapeutics' Net Margin fell 169752600.0% to 18405.73% in Q4 2024 from the same period last year, while for Sep 2025 it was 52019.79%, marking a year-over-year decrease of 510493000.0%. This contributed to the annual value of 7965.76% for FY2024, which is 63262600.0% down from last year.
- According to the latest figures from Q4 2024, Avalo Therapeutics' Net Margin is 18405.73%, which was down 169752600.0% from 9251.81% recorded in Q3 2024.
- In the past 5 years, Avalo Therapeutics' Net Margin registered a high of 9251.81% during Q3 2024, and its lowest value of 18405.73% during Q4 2024.
- Over the past 4 years, Avalo Therapeutics' median Net Margin value was 26.05% (recorded in 2021), while the average stood at 1156.77%.
- Within the past 5 years, the most significant YoY rise in Avalo Therapeutics' Net Margin was 114670600bps (2024), while the steepest drop was -169752600bps (2024).
- Over the past 4 years, Avalo Therapeutics' Net Margin (Quarter) stood at 33.33% in 2020, then tumbled by -189bps to 29.68% in 2021, then crashed by -4720bps to 1430.47% in 2023, then plummeted by -1187bps to 18405.73% in 2024.
- Its Net Margin stands at 18405.73% for Q4 2024, versus 9251.81% for Q3 2024 and 1430.47% for Q4 2023.